Aldeyra Therapeutics in net loss of approximately $13.3 million in Second Quarter 2019
Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Expected to be Completed in Fourth Quarter 2019…
Pharmaceuticals, Biotechnology and Life Sciences
Part 1 of Adaptive Phase 3 RENEW Trial in Dry Eye Disease Expected to be Completed in Fourth Quarter 2019…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Axcella Health (Nasdaq: AXLA), a biotechnology company pioneering the research and development of novel multifactorial interventions to address…
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Peter Dannenbaum…
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the…
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 23, 2019 the Compensation Committee of…
FDA approved IND for UCARTCS1 – first allogeneic CAR T-cell product candidate in multiple myeloma (MM) Ongoing construction of in-house…
– Progressing our lead program, AB928, a potential best-in-class dual A2a/A2b receptor antagonist, into multiple dose-expansion cohorts in 2H19, including…
IRVING, Texas–(BUSINESS WIRE)–Vizient, Inc. has released its July 2019 Drug Price Forecast projecting health systems, including inpatient and non-acute environments,…
NEW YORK–(BUSINESS WIRE)–Schrödinger today announced the appointment of veteran pharmaceutical executive Gary Sender to its Board of Directors, as well…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Akebia Therapeutics, Inc. (Nasdaq: AKBA), today announced that its wholly-owned subsidiary, Keryx Biopharmaceuticals, Inc., and its licensor Panion…